The prognosis of patients with poor-risk or relapsed hematological malignancies is dismal. The dose intensification necessary to achieve subsequent CR is limited by the toxicity of chemotherapy. Treatment intensification with double allogeneic HSCT (dHSCT) may enhance the antileukemic effect and reduces treatment-related toxicity associated with prolonged aplasia during reinduction. We evaluated this approach in 23 patients, nine with primary refractory disease or relapse after conventional chemotherapy (group I) and 14 with relapses after allogeneic HSCT (group II). Double HSCT was feasible in all patients. At the end of the observation period, 6 of 23 (26%) patients were still alive and in remission with a median observation time of 60 months (1-153). The overall survival probability at 1 year was 41% (95% confidence interval (CI), 21-62%), transplant-related mortality (TRM) 28% (9-47%) and the incidence of relapse 42% (18-66%). The TRM in groups I and II were 22 and 36% and the relapse rate 33 and 50%, respectively. In conclusion, we have shown the feasibility of dHSCT with an acceptable TRM, irrespective of a previous allogeneic HSCT. Whether this approach offers a survival benefit for patients with poor-risk leukemias has to be tested in larger prospective trials.
Introduction
Treatment of relapsed hematological malignancies or poorrisk leukemia remains a challenge, and there is a substantial need to improve the outcome of such patients. Responses to conventional reinduction chemotherapy or allogeneic hematopoietic SCT (HSCT) without previous CR are generally poor with low rates and short duration of remissions. [1] [2] [3] Likewise, the therapeutic options for patients with relapses after allogeneic HSCT are limited. Several approaches have been evaluated, including donor-lymphocyte infusions with or without previous reinduction chemotherapy and direct allogeneic HSCT with myeloablative conditioning or high-dose melphalan. [3] [4] [5] [6] [7] Results with direct allogeneic HSCT are unsatisfactory, but previous reinduction chemotherapy adds toxicity by inducing prolonged aplasia. 8, 9 Thus, the majority of these patients will receive a best supportive care strategy, and will eventually succumb to the underlying disease. Dose intensification with reinduction chemotherapy followed by direct allogeneic HSCT is often hindered by its high toxicity. An autologous HSCT with previous high-dose chemotherapy followed by an allogeneic HSCT is a possible approach for such patients. However, in the majority of cases, no autologous stem cells are available. Thus, we investigated double allogeneic HSCT (dHSCT) from the same donor as an approach for treatment intensification without increasing toxicity by prolonged aplasia. After intensive conditioning to reduce the leukemic burden, a first T-cell-depleted stem cell transplant mimics an autologous HSCT and is intended to accelerate hematological recovery, thereby adding safety to the procedure without causing graft-vs-host disease (GVHD). A second T-cell replete dHSCT is administered directly after hematological recovery using high-dose pretransplant conditioning regimens. This transplant is intended to boost the cytoreduction of the leukemic cells and to establish a graft-vs-leukemia (GVL) effect. The transplant procedure is based on the experience of two previously published patients and was applied in 23 selected patients. 10 
Patients and methods

Study design and definitions
This retrospective single center cohort analysis evaluated the feasibility and toxicity of our approach in using dHSCT as a treatment for poor-risk hematological malignancies. The patients were divided into two groups: acute or chronic leukemia with poor-risk features but without previous allogeneic HSCT (1), or acute or chronic leukemia with relapse after allogeneic HSCT (2) . Poor-risk features in the first group were defined as follows: secondary acute leukemia, relapses of acute leukemia after conventional chemotherapy, primary induction failure (PIF) and chronic myelogenous leukemia (CML) in accelerated phase/blast crisis. PIF was defined as failure of leukemia clearance (45% residual blasts in the BM) after two or more cycles of induction chemotherapy. Duration of first remission was defined as the time from initial diagnosis to relapse in patients not having had an HSCT and as the time from the first HSCT to relapse in patients who had had a previous HSCT. Remission after dHSCT was defined as the time from the second dHSCT to relapse. Eligibility criteria were written informed consent and willingness of patients, and donors as well as a sufficiently good general health status for such an intensive treatment (Karnovsky score 480%, normal renal, cardiac and pulmonary function, no uncontrolled infections). . One patient (UPN 1136) underwent the first syngeneic dHSCT without conditioning because of severe protracted aplasia after chemotherapy, and one patient (UPN 702) with ALL was conditioned with BEAM. The second T-replete HSCT was carried out immediately after recovery from the first HSCT and was based on TBI (TBI, 12 Gy) and CY/etoposide (Cy/TBI/VP16, n ¼ 5), CY/TBI (Cy/TBI, n ¼ 3) or BU and CY (Bu/Cy, n ¼ 13). Patients with relapses after a previous HSCT who had already received TBI with the first HSCT were treated with Bu/Cy, whereas patients receiving initial regimens without irradiation received a TBI-containing regimen. As a consequence, patients who had had no previous HSCT received a TBI-based regimen (P ¼ 0.006) more often. Two patients with CML received fludarabine and single-dose TBI (2 Gy) as conditioning.
Transplant technique
Stem cell harvesting
The stem cells for both dHSCTs were collected in 1-2 consecutive apheresis sessions starting 1 day before the first dHSCT. All donors were harvested after a 4-to 6-day mobilization with G-CSF (Filgrastim, 10 mg/kg body wt/ day). The aim was to collect at least 8 Â 10 6 CD34-positive cells per kg body wt of the recipient. If the cell number after the first apheresis session was not sufficient, a second session was carried out on the day of the first dHSCT. The fresh stem cells were partially cryopreserved for the second dHSCT (at least 4 Â 10 6 CD34-positive cells per kg body wt) and the remainder of the stem cells was T-cell depleted at the day of the first dHSCT. T-cell depletion was carried out by a two-step ex vivo purification procedure (Clini-MACS cell-collection system). The first step was CD4/CD8 depletion followed by CD34 enrichment. The median number of CD34-positive cells at the first dHSCT was 3.5 Â 10 6 /kg body wt (range 1.5-9.8) and 6.1 Â 10 6 /kg body wt (range 2.0-14.1) at the second dHSCT. The median number of T-cells in the first dHSCT was 0.02 Â 10 5 /kg body wt (0.01-0.3).
Statistical analysis
Baseline characteristics are shown as means, medians and proportions. Survival probability was calculated by the Kaplan-Meier estimator. All statistical analyses were carried out with SPSS version 17 for Macintosh.
Results
A total of 23 patients underwent dHSCT by the SCT team of the University Hospitals, Basel, between 1995 and 2009. Baseline characteristics of all patients are outlined in Table 1 . The median age of patients at dHSCT was 42 years (range 5-70). Fourteen (61%) patients received dHSCT for relapse after a previous allogeneic HSCT, 9 (39%) for leukemia with poor-risk features. All patients received PBSC transplants. Patients received dHSCT from an HLA-identical sibling (21), a 5/6 HLA-identical family donor (1) and from a syngeneic twin (1) . None of the donors had problems during or after stem-cell collection.
Double allogeneic HSCT was feasible in all patients with acceptable toxicity. The median time between the first and Double HSCT for hematological malignancies G Stussi et al the second dHSCT was 30 days (24-61 days). All patients showed neutrophil engraftment after the first dHSCT, and all but one patient after the second dHSCT. At the end of the observation period, 6 of 23 (26%) patients were still alive and in remission. The median observation time of the six surviving patients was 60 months (range 1-153). As shown in Figure 1 , overall survival probability at 1 year was 41% (95% confidence interval (CI), 21-62%), transplant-related mortality (TRM) 28% (9-47%) and incidence of relapse 42% (18-66%). Age, underlying disease and gender of the recipient and donor did not influence overall survival, TRM or relapse incidence. However, as the CIs were large, the statistical analyses have to be interpreted with caution (data not shown).
Double HSCT in poor-risk leukemia without previous HSCT Details of the nine patients receiving dHSCT without previous allogeneic HSCT are shown in Table 2 . Six patients were transplanted for AML, two for CML and one for Ph chromosome-positive ALL. At the time of dHSCT, three patients had had a relapse after chemotherapy, 2 secondary AML, two PIF and two CML in blast crisis. Relapses after chemotherapy occurred 47, 255 and 692 days after the initial diagnosis. One of the patients received HAM reinduction before dHSCT but did not achieve CR.
DHSCT was chosen as a rescue therapy for this patient. All patients had neutrophil engraftment after the first and second dHSCT. Double HSCT was generally well tolerated, but one patient died of toxicity 15 days after the second dHSCT and another died 1730 days after the second dHSCT because of a secondary carcinoma, resulting in a TRM of 22%. Five (56%) patients had acute GVHD, and two (22%) patients had chronic GVHD. None of the patients had grade III or IV acute GVHD. Overall, four of nine (44%) patients are still alive and disease free with a median survival time of 60 months (range 1-84 months). Three (33%) patients died of relapse. Notably both patients with CML after reduced-intensity conditioning relapsed early after dHSCT and died because of disease progression. The 1-year survival probability was 51% (95% CI, 16-85%).
Double HSCT after previous allogeneic HSCT Fourteen patients were treated with dHSCT for relapses after allogeneic HSCT, nine patients with AML, three with ALL and two with CML. As shown in Table 3 , 10 patients experienced a first relapse and four patients a second relapse before dHSCT. The median time from the first HSCT to relapse was 264 days (range 118-2083 days). Double HSCT was administered at a median of 307 days (range 208-2212 days) after the first HSCT. Two patients were treated with reinduction chemotherapy before proceeding to dHSCT because of a time delay due to logistic reasons. All patients had neutrophil engraftment after the first dHSCT, and all but one patient after the second dHSCT. The patient without engraftment died of sepsis with multiorgan failure on the day of the second dHSCT. Overall, two (14%) patients are still alive after dHSCT; the respective follow-up times are 995 and 4585 days. Eight (57%) patients died of relapse or progressive disease, with a median time to relapse of 151 days (range: 42-1137 days). Five (36%) patients died of TRM with a median survival time of 15 days (range 0-82 days). The causes of TRM were sepsis (3), veno-occlusive disease (1) and toxicity leading to heart failure (1). The 1-year probability of survival was 36% (95% CI, 11-61%). Acute GVHD after the second T-replete dHSCT occurred in four patients with a maximum of grade III (29%). One patient receiving a non-T-cell-depleted stem-cell product experienced acute GVHD grade II, 19 days after the first dHSCT.
Surviving patients are described in more detail. The first patient (UPN 326) was transplanted for CML in blast crisis. After two previous allogeneic transplants with myeloablative conditioning, he received dHSCT in 1996 for the second myeloid blast crisis 10 years after the initial diagnosis and 6 years after the last HSCT. He experienced acute GVHD grade I 6 days after the second dHSCT but no further complications. To date, he is doing well and is in Overall survival probability at 1 year was 41% (95% CI, 21-62%). (b) Transplant-related mortality at 1 year was 28% (9-47%) and cumulative incidence of relapse was 42% (18-66%).
Double HSCT for hematological malignancies G Stussi et al a complete molecular remission. The second patient (UPN 1159) with intermediate risk AML in first CR underwent reduced-intensity conditioning with fludarabine and TBI (2 Gy) at the first HSCT because of his age (70 years). He rejected the first transplant despite a rapid tapering of the immunosuppression and donor-lymphocyte infusions. He then remained pancytopenic for 3 months until a diagnosis of relapse was made. He was treated with dHSCT from the same donor, with high-dose melphalan for the first dHSCT and standard Cy/TBI for the second dHSCT. To date, he remains in CR, receiving small doses of prednisone and CYA because of chronic GVHD of the upper gastrointestinal tract.
Discussion
In this retrospective single-center study, we evaluated the possibility of treatment intensification with dHSCT as a rescue therapy for patients with poor-risk hematological malignancies. The role of dose intensification with double autologous and sequential autologous/allogeneic HSCT has been well established in the treatment of multiple myeloma and relapsed lymphoma, [11] [12] [13] whereas dHSCT has rarely been reported. 10, 14 Several authors have tried dose intensification by increasing the dose of irradiation or chemotherapy. [15] [16] [17] However, the benefit of fewer relapses because of more intensive chemo-radiotherapy on overall survival was offset by a higher therapy-related mortality. Likewise, reinduction chemotherapy with sequential dosing schemes has the potential to induce a second CR before transplantation, but is associated with high toxicity. 16 Thus, we aimed to intensify the chemotherapy dose given by using two myeloablative conditioning regimens administered within a short period while reducing toxicity by shortening the aplasia time. The possible advantage of dHSCT is the added antitumor effect by two conditioning regimens without the toxicity of previous reinduction. The T-cell-depleted first stem cell rescue mimics an autologous HSCT by accelerating hematological recovery and allowing early repeat treatment. The second T-cell-replete dHSCT adds an antitumor effect by virtue of a second myeloablative conditioning regimen and establishes an allogeneic GVL effect. This study aimed to prove the feasibility of such an approach for patients and their respective donors. The limitations of our study are the small patient numbers, disease heterogeneity and the retrospective analysis.
Patients with relapsed leukemia or primary refractory disease who have not undergone previous allogeneic HSCT may derive an advantage from dHSCT with an overall survival after 1 year of 50%. In the past, several approaches have been evaluated for the treatment of relapsed or primary refractory leukemia, such as intensive reinduction chemotherapy using different regimens followed by HSCT. [17] [18] [19] [20] [21] [22] [23] [24] However, with this approach, only one-third of patients achieved CR and the intensive pretransplant chemotherapy was associated with considerable treatmentrelated toxicity. Consequently, median overall survival for both AML 17, 21, 22 and ALL 3, 23, 24 is only a few months and long-term survivors are almost exclusively observed after allogeneic HSCT. Direct autologous or allogeneic HSCT without previous reinduction chemotherapy may be an alternative approach for such patients [25] [26] [27] and is associated with a reduction in toxicity. [28] [29] [30] Alternatively, one study has tried to enhance the antileukemic effect by the rapid sequential use of cytoreductive chemotherapy, cytokine stimulation and donor lymphocyte infusions followed by an RIC allogeneic HSCT. 31 Although patient characteristics vary between studies, our results compare favorably with these studies. However, the number of patients in this group was small and clear patient selection criteria are needed to define which patients could profit from a dHSCT approach upfront.
Treatment of relapse after allogeneic HSCT is even more challenging with very limited options. Several approaches have been evaluated in the past: (1) reduction of the immunosuppression, 23 (2) donor lymphocyte infusions with or without previous reinduction chemotherapy, 32 (3) second single allogeneic HSCT 6, 8, [33] [34] [35] [36] [37] and (4) dHSCT. 10, 14 However, only a small percentage of relapsed patients are well enough for intensive treatment. 38 In a retrospective EBMT analysis of 117 selected patients relapsing after HSCT, 43% of the patients receiving reinduction therapy achieved a second remission with a median duration of 12 months. In contrast, the median survival of patients with best supportive care and those who did not reach a CR was 4 months. 2 Some case reports suggest occasional long-term survivors after conventional reinduction chemotherapy 39 or second HSCT. 40 Barrett et al. analyzed 90 patients receiving second HSCT for relapsed leukemia. In this study, the actuarial survival at 4 years was 12%, relapse mortality 28% and TRM 41%. Prognostic factors for remission induction were a low-blast count at the time of transplant and a normal karyotype at presentation, number of previous remissions at HSCT, and a long interval between HSCT and relapse. 2, 39 In our group of patients with acute leukemia, relapsing after previous allogeneic HSCT, long-term survival was unsatisfactory despite dHSCT. Only two patients were still alive; one patient is in CR 33 months after dHSCT for relapsed AML with an intermediate cytogenetic profile, and with slow disease kinetics. It is interesting to note that the first transplant before relapse was performed after reduced intensity conditioning. Therefore, only one patient with relapse after two transplants using myeloablative conditioning is still alive. He remains in complete molecular remission 22 years after the initial diagnosis of CML and 12 years after dHSCT. Five (36%) patients died of TRM and seven (50%) patients of relapse as observed by others. 6, 35 Interestingly, both patients with CML tolerated dHSCT without major problems despite an advanced disease stage and many previous treatments and achieved a further complete molecular remission with durations of 2 and 12 years. Thus, both patients seem to have profited from the intensified treatment.
In conclusion, dHSCT can be carried out with acceptable toxicity and TRM, and induces long-term remission in some patients. In particular, patients with primary refractory leukemia or relapse after conventional chemotherapy may benefit from dHSCT. In contrast, patients with relapse after a first standard allogeneic HSCT seem not to profit from this approach because of the high incidence of TRM and relapse. dHSCT should be further evaluated in a prospective study for patients with refractory and relapsed leukemia.
